We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

SAPA-DC 2016 Founding Conference

17 September 20168:00 AM - 4:30 PM (EST)

Nowadays the U.S. and China are the most important pharmaceutical markets for drug development and manufacturing. During 2015, the U.S. Food and Drug Administration (FDA) approved 45 novel drugs, hitting a 19-year record high, which is extremely encouraging for the pharmaceutical industry worldwide. In the meantime, the China Food and Drug Administration (CFDA) has started a reform aiming to solve backlogs of review and approval process for drugs and medical devices. This extensive reform has brought many critical challenges for every multinational pharmaceutical company.

We will offer you the latest legal and regulatory information, provide face-to-face opportunities with directors from both FDA and CFDA, and bring the top regulatory professionals to help you tap into these new situations.

Hogan Lovells US LLP
Columbia Square
555 Thirteenth Street, NW
Washington, D.C.
United States, 20004

17 September 2016
8:00 AM - 4:30 PM (EST)

From Hogan Lovells

Xin Tao
Senior Associate
Washington, D.C.

Loading data